infections in hsct
DESCRIPTION
Infections in HSCT. Meng Yao Lu Department of Pediatrics National Taiwan University Hospital October 17, 2009. HSCT patients. Highly susceptible to infections primary diagnosis chemotherapy and anti-GVHD medicines pancytopenia indwelling catheters mucosal and skin breakdown - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/1.jpg)
Infections in HSCT
Meng Yao Lu
Department of Pediatrics
National Taiwan University Hospital
October 17, 2009
![Page 2: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/2.jpg)
HSCT patients . . .
Highly susceptible to infectionsprimary diagnosischemotherapy and anti-GVHD medicinespancytopenia indwelling cathetersmucosal and skin breakdownparenteral nutritionbroad spectrum antibiotics
![Page 3: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/3.jpg)
Infections in transplant . . .
prolonged fever in >90%
50% have documented infections bacterial >> fungal > viral
infectious mortality of 4%-33%
bacterial and fungal infections predominate in the first post-transplant month
after 100 days, viral and encapsulated bacterial infections predominate
risk depends on type of transplant allogeneic unrelated >> allogeneic related > autologous
![Page 4: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/4.jpg)
Three Periods of susceptibility . . .early recovery or “pre-engraftment” first several weeks after transplant related to neutropenia, chemotherapy induced mucositis and
CVL placement
mid-recovery or “early post-engraftment” second and third months after transplant related to acute GVHD, decreased cellular immunity
secondary to GVHD, immunosuppressive therapy and viral infections (e.g. CMV) and indwelling CVLs
late recovery interval beyond three months after transplant related to decreased cellular immunity secondary to chronic
GVHD, nonspecific suppressor cells due to chronic GVHD, reduced opsonization, decreased reticuloendothelial function, immunoglobulin G subclass deficiencies
![Page 5: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/5.jpg)
PreventionConscientious hand washing
meticulous oral hygiene
low bacterial diet fruits & fresh salads --> aerobic GN rodspepper --> Aspergillus
HEPA filtration
decontaminationnot universally practiced
Laminar Air Flow (LAF) rooms
Surveillance cultures
![Page 6: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/6.jpg)
Timeline of Infections
![Page 7: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/7.jpg)
Common sites of infection . . .
blood (40.1%)GI tract (12.7%)skin (12.7%)upper respiratory tract (11.7%)lung (10.7%)urinary tract (6.8%)hepatobiliary system (1.6%)central nervous system (1.6%)eye (0.7%)
Blood. November 1995, Ochs et al.
![Page 8: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/8.jpg)
The common bacteria . . .Gram positives GP bacteremia rates now
exceed GN rates enter via central lines,
skin and occasionally via GI tract
Staph epidermidis Staph aureus enterococcus α hemolytic strep Corynebacterium spp.
Gram negatives the most virulent and a
frequent cause of morbidity & mortality
enter via mucosa/GI tract, damaged skin, or central lines
Eschericia coli Klebsiella spp. P. aeruginosa Pseudomonas Enterobacter Acinetobacter Proteus Serratia
![Page 9: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/9.jpg)
Antibacterial Therapy . . .Pre-Transplant Prophylaxis no longer routinely implemented at all transplant centers included oral nonabsorbable agents (e.g. Vancomycin, Gentamicin,
neomycin, colistin and polymyxin B) use of anti-PCP therapy is universal for all centers
Empiric Treatment prompt administration of broad spectrum coverage begin usually with third-generation cephalosporin or broad-spectrum
penicillin, add aminoglycoside with septic picture reevaluate if fever persists (> 3 days) and no + cultures
Specific Therapy tailor to identification and sensitivity panels may await confirmation of S. epidermidis infection with repeat cultures
![Page 10: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/10.jpg)
The common fungi . . .
Candida sp. granulocytopenia cell-mediated immunity reactivation or
colonization TPN with high CHO broad spectrum
antibiotics resistance to prophylaxis
Aspergillus sp. granulocytopenia hi-grade GVHD broad spectrum
antibiotics dusty building
renovation hospital environment reactivation or
colonization life style corticosteroids
![Page 11: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/11.jpg)
![Page 12: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/12.jpg)
![Page 13: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/13.jpg)
Aspergillus . . .
inhalation of spores
colonization of the Sino-pulmonary tree
invasion and dissemination
lack of specific diagnostic test
mortality approaches 90% with invasion
![Page 14: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/14.jpg)
Epidemiology of Aspergillosis in HSCT Recipients
Bimodal Distribution Neutropenic phase
Depth Duration
Post engraftment phase GvHD Steroid use CSA/Tacrolimus Mucosal disruption CMV disease
![Page 15: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/15.jpg)
Aspergillosis : Clinical Manifestations
Pneumonia Pleuritic pain Cough Hemoptysis
Sinusitis Nasal congestion Eschars Epistaxis Palatal hemierythema Disseminated infection (CNS)
![Page 16: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/16.jpg)
Antifungal Therapy . . .Prophylaxis Polyenes (nystatin) Amphotericin B
broad spectrum extensive potential
toxicities Azoles
intravenous versus oral
Echinocandins Caspofungin Micafungin
Treatment Amphotericin B
0.5-1.5 mg/kg/day IV systemic greatly increased
toxicities, especially with concurrent CYA
Azoles Voriconazole
Echinocandins Caspofungin Micafungin
![Page 17: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/17.jpg)
The common viruses . . .Herpesviruses CMV- associated with high rates of mortality EBV - PTLD HSV- 70-80% of transplant pts. are seropositive VZV- 20-50% of transplant pts. develop zoster
Epstein-Barr virus (EBV) 0.5% of allogeneic BMT recipients develop EBV-LPS
HHV6
Respiratory Viruses RSV, parainfluenza viruses, rhinovirus and influenza A & B
Enteroviruses adenovirus, coxsackie virus and rotavirus
![Page 18: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/18.jpg)
![Page 19: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/19.jpg)
Antiviral Therapy . . .Prophylaxis CMV
CMV-neg. blood pdts ganciclovir
HSV Acyclovir
VZV usually unnecessary
Treatment CMV
Ganciclovir Foscarnet Cidofovir immunoglobulin
HSV hi-dose acyclovir foscarnet
VZV hi-dose acyclovir
EBV donor lymphocytes
![Page 20: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/20.jpg)
HSV 1 & 2 infection
Predominantly during neutropenia and within day 30 of HSCT
Mucocutaneous (oral/genital), esophageal, disseminated
Routine prophylaxis use of acyclovir
Resistance is uncommon
![Page 21: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/21.jpg)
CMV infection
CMV infection remains as an important cause of morbidity and mortality in children undergoing HSCT.
Treatment StrategiesProphylactic therapyPre-emptive therapy after periodic
surveillance
![Page 22: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/22.jpg)
0.0
0.2
0.4
0.6
0.8
1.0
3 4 5 6 7
Log viral load (genomes/ml)
Pro
bab
ilit
y o
f d
isease
Cope et al (1997) J Infect Dis 176: 1484-90
Suppression of CMV reduces disease probability
![Page 23: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/23.jpg)
Risk factor Transplant type and
conditioning
Peak incidence Day+ 45-60 days
MUD > MRD > autograft
BMT > PBSCT ?
Conditioning Myeloablative> non-myeloablative < 100 days Myeloablative=non-myeloablative at 1 year
T cell depletion In vivo (ATG, Campath) Ex vivo (CD34 selection)
![Page 24: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/24.jpg)
Interventions to control CMV
Primary infection
Latency
Reactivation ( +ve pp65 or PCR)
Disease
Prophylaxis
Pre-emptive therapy
CMV NaivePrevent infectionCMV Neg Donor, Leokodepletion
![Page 25: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/25.jpg)
CMV viral load and pre-emptive antiviral therapy
![Page 26: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/26.jpg)
Therapeutic approaches to control CMV replication
Prophylaxis Universal or targeted Eliminates direct and
indirect effects of CMV
Subset of patients remain at risk of late CMV infection/disease after cessation of prophylaxis
Pre-emptive therapy Targets individuals
based on their virologic markers
Minimises drug exposure
Patients may require more than one treatment
May not eliminate the indirect effects of CMV
Forum debate (2001) Rev Med Virol 11:73-86
![Page 27: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/27.jpg)
CMV viral load and pre-emptive antiviral therapy
Preemptive treatment : highly effective
Detection
= pp65 antigenemia assay
= pp67 mRNA assay :sensitive but seldom use
= DNA detection methods
= Quantitative real-time PCR assays
![Page 28: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/28.jpg)
EBV associated Post-Transplant Lmyphoproliferative Disorder
![Page 29: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/29.jpg)
EBV PTLD
![Page 30: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/30.jpg)
![Page 31: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/31.jpg)
Therapy for EBV PTLD
Decrease immunosuppression
Rituximab
Antiviral agent
Donor-derived EBV-specific CTLs
Chemotherapy
![Page 32: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/32.jpg)
Herpes Zooster/Varicella
Primary vs reactivated
High mortality rate in disseminated infection High dose acyclovir
Prevention Acyclovir prophylaxis VZIG within 96h of exposure Immunization of seronegative household
membersw Contact and respiratory precautions
![Page 33: Infections in HSCT](https://reader031.vdocuments.site/reader031/viewer/2022020921/5681436a550346895dafe892/html5/thumbnails/33.jpg)
Immunoglobulins
No role in Autologous transplant recipients
Allogeneic recipients: 400-500 mg/kg weekly from day 7 to day 100+
Reported effects: decrease bacterial sepsis decrease CMV disease decrease interstitial pneumonitis decrease acute GVHD decrease bacterial infections decreased mortality